霍奇金淋巴瘤的转化科学
霍奇金淋巴瘤(HL)的恶性细胞在密集的炎症与免疫微环境中仅占少数,NF-κB和JAK/STAT等信号通路失调维持其生存。基因组医学进步提升了对此类罕见肿瘤细胞及细胞-微环境信号机制的认识,现有治疗在多数年轻患者中疗效优异,但老年患者预后较差、高效联合化疗毒性及高危患者复发仍是问题。生物学驱动疗法(抗CD30抗体偶联药物、细胞免疫治疗及免疫调节尤其是检查点抑制剂)已改变复发/难治患者的治疗策略,未来挑战在于将免疫治疗前移以减少毒性并预防复发。
要点
- HL恶性细胞为微环境中的少数群体,NF-κB和JAK/STAT通路失调维持其生存。
- 现有治疗在多数年轻患者中疗效优异,但老年预后差、化疗毒性和高危复发仍是问题。
- 抗CD30抗体偶联药物、细胞免疫治疗及检查点抑制剂已改变复发/难治患者治疗策略。
核心结论
- 深入理解疾病生物学有助于对患者进行 upfront 预后判断、定义治疗监测新方法并识别新治疗靶点。
- 生物学驱动疗法已改变复发/难治性HL患者的治疗算法,未来挑战在于将免疫治疗更早纳入治疗算法以减少毒性和预防复发。
研究设计与样本
- 本文为转化科学综述,聚焦霍奇金淋巴瘤的肿瘤细胞与微环境相互作用、失调信号通路及生物学驱动治疗进展。
主要发现
- HL恶性细胞在密集细胞微环境中以少数群体存在,微环境主要由炎症和免疫细胞组成,部分病例伴纤维化。
- 维持HL微环境的失调信号通路包括核因子-κB(NF-κB)和Janus激酶/信号转导与转录激活因子(JAK/STAT)通路。
- 基因组医学进步使罕见肿瘤细胞特征得到更好刻画,并增进了对恶性细胞与其微环境之间信号机制的理解。
- 现有HL治疗在多数年轻患者中产生优异临床结局,但老年患者结局较差、高效联合化疗方案存在毒性、高危患者仍会复发。
临床怎么用
- 作者指出,对疾病生物学的更好理解有助于对患者进行 upfront 预后判断、定义治疗监测新方法并识别新治疗靶点。
- 作者指出,生物学驱动疗法包括抗CD30抗体偶联药物、细胞免疫治疗和免疫调节尤其是检查点抑制剂,已改变复发/难治患者的治疗算法。
- 作者指出,未来挑战在于将免疫治疗更早纳入治疗算法以减少毒性和预防HL患者复发。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hodgkin Lymphoma (HL) is an unusual B-cell lymphoma because the malignant cells exist as a minority population in a densely cellular microenvironment. The microenvironment is comprised predominately of inflammatory and immune cells with fibrosis in some cases. There are multiple dysregulated signalling pathways that sustain HL within this microenvironment, such as the Nuclear factor-κB and Janus kinase/signal transducers and activators of transcription pathways. Advances in genomic medicine have enabled a better characterisation of the rare tumour cells and improved our understanding of the signalling mechanisms that exist between the malignant cell and its microenvironment. Current therapy for HL produces excellent clinical outcomes in most younger patients. However, problems with current treatment approaches include poorer outcomes in the elderly, toxicity of highly-effective combination chemotherapy regimens and relapse in high-risk patients. Better understanding of disease biology aids in upfront prognostication of patients, defines new methods for treatment monitoring and assists in the recognition of novel targets for therapy. Biology-driven therapies, including anti-CD30 antibody conjugates, cellular immunotherapies and immune modulation, particularly with checkpoint inhibitors, have changed treatment algorithms for relapsed/refractory patients. Future challenges exist in incorporating immune-based therapies earlier in treatment algorithms to reduce toxicity and prevent relapse for patients with HL.
引用
- Cirillo M, Reinke S, Klapper W, et al. The translational science of hodgkin lymphoma. Br J Haematol. 2018. PMID: 30417946. doi:10.1111/bjh.15658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。